Skip to main content

Advertisement

SpringerLink
Log in

Antisense and sensibility

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

It took a leap of faith for researchers to believe that antisense technology might lead to novel medicines, but that commitment could soon pay off.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: A schematic of the mode of action of antisense drugs.

© Mark Sokoloff

Figure 2: First-generation and second-generation chemistries used to generate antisense oligonucleotides with characteristics more suitable for medicines.

© Bob Crimi

References

  1. Dove, A., Nat. Biotechnol. 18, 19 (2000).

    Article  CAS  Google Scholar 

  2. Niiler, E., Nat. Biotechnol. 19, 898–899 (2001).

    Article  CAS  Google Scholar 

  3. Tyler, B.M. et al. Proc. Natl. Acad. Sci. USA 96, 7053–7058 (1999).

    Article  CAS  Google Scholar 

  4. Sayda, M.E. et al., Nature 411, 494–498 (2001).

    Article  Google Scholar 

Download references

Authors
  1. Alan Dove
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dove, A. Antisense and sensibility. Nat Biotechnol 20, 121–124 (2002). https://doi.org/10.1038/nbt0202-121

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0202-121

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation